STN1012600 ophthalmic solution 0.002% + STN1012600 ophthalmic solution 0.002% + STN1012600 ophthalmic solution 0.002% and Timolol ophthalmic solution 0.5%
Phase 3Completed 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Open Angle Glaucoma, Ocular Hypertension
Conditions
Open Angle Glaucoma, Ocular Hypertension
Trial Timeline
Aug 8, 2022 → Jan 30, 2024
NCT ID
NCT05503901About STN1012600 ophthalmic solution 0.002% + STN1012600 ophthalmic solution 0.002% + STN1012600 ophthalmic solution 0.002% and Timolol ophthalmic solution 0.5%
STN1012600 ophthalmic solution 0.002% + STN1012600 ophthalmic solution 0.002% + STN1012600 ophthalmic solution 0.002% and Timolol ophthalmic solution 0.5% is a phase 3 stage product being developed by Santen Pharmaceutical for Open Angle Glaucoma, Ocular Hypertension. The current trial status is completed. This product is registered under clinical trial identifier NCT05503901. Target conditions include Open Angle Glaucoma, Ocular Hypertension.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05503901 | Phase 3 | Completed |
Competing Products
20 competing products in Open Angle Glaucoma, Ocular Hypertension
Other Products from Santen Pharmaceutical
Eybelis ophthalmic solution 0.002%Approved
85
Aflibercept Injection [Eylea]Approved
85
DE-117B Eye Drops + LatanoprostPhase 3
77
3% DE-089 ophthalmic solution + 0.1% sodium hyaluronate ophthalmic solutionPhase 3
77
DE-111 ophthalmic solution + Tafluprost ophthalmic solution 0.0015% + Concomitant use of tafluprost ophthalmic solution 0.0015% plus timolol ophthalmic solution 0.5%Phase 3
77